Sakar Healthcare share news and announcements
NSE: SAKARPharmaceuticals & BiotechnologySmall Cap
Last close ₹889.80down ₹62.00 (6.51%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹951.80.
52-week range of traded prices to 23 Oct 2026
₹352.00Low, 27 Oct 2025₹1,229.85High, 23 Sep 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,980 Cr1,357th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 23 Oct 2026
- 46.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 23 Oct 2026
- 5.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 23 Oct 2026
- 13.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 23 Oct 2026
- 16.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 23 Oct 2026
- 0.13
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,47,09017.5% delivered
Sakar Healthcare share news and announcements
453 announcements, routine notices left out, newest first. Page 9 of 10.
Jul 2018
20 Jul · Board meeting
May 2018
30 May · Board meeting
Apr 2018
Mar 2018
28 Mar · Board meeting
23 Mar · Board meeting
20 Mar · Amendment to AOA/MOA
Feb 2018
21 Feb · Legal
Exchange has sought clarification from Sakar Healthcare Limited with respect to announcement dated 21-Feb-2018, regarding " Sakar Healthcare Limited has informed the Exchange regarding Change in Company Secretary / Compliance Officer.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.21 Feb · Change in Company Secretary/Compliance Officer
21 Feb · Board meeting
16 Feb · Board meeting
5 Feb · Address Change
Jan 2018
Dec 2017
Nov 2017
20 Nov · Legal
Exchange has sought clarification from Sakar Healthcare Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted The response of the Company is awaited.14 Nov · Board meeting
4 Nov · Board meeting
4 Nov · Board meeting
Sep 2017
Aug 2017
23 Aug · Updates
Jul 2017
31 Jul · Board meeting
20 Jul · Board meeting
Jun 2017
May 2017
30 May · Board meeting
30 May · Board meeting